Sigma-Tau announced the launch of Cystaran (cysteamine ophthalmic solution), the first FDA-approved therapy for the treatment of corneal cystine crystal accumulation in patients with cystinosis.
Corneal cystine accumulation can lead to ocular complications such as squinting, foreign body sensations, changes in visual acuity, corneal haziness and photophobia (eg, sensitivity to light). Cystaran ophthalmic solution was approved by the FDA in October 2012 and has also been granted Orphan Drug Status.
Cysteamine acts as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides and reduces corneal cystine crystal accumulation.
Cystaran 0.44% ophthalmic solution is available in a 15mL bottle.
For more information call (866) 634-2765 or visit the Cystaran website.